Dietary restriction of energy and sugar results in a reduction in human cytochrome P450 2E1 activity

British Journal of Nutrition

Volumn 82, Issue 4, 1999, Pages 257-262

  Leclercq, Isabelle ^a   Horsmans, Yves ^a   Desager, Jean Pierre ^a   Pauwels, Stanislas ^a   Geubel, André P ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Aminopyrine; Chlorzoxazone; Cytochrome P450; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOPHENAZONE; ASPARTATE AMINOTRANSFERASE; CHLORZOXAZONE; CYTOCHROME P450; LIVER ENZYME; TECHNETIUM 99M;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BREATH ANALYSIS; CALORIC INTAKE; CLINICAL ARTICLE; DIET RESTRICTION; DIETITIAN; ECHOGRAPHY; ENZYME ACTIVITY; FATTY LIVER; FEMALE; HUMAN; INTERVIEW; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER PARENCHYMA; LIVER WEIGHT; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUGAR INTAKE;

EID: 0032821468     PISSN: 00071145     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0007114599001452     Document Type: Article

References (33)

1. Aarsland A, Chinkes D & Wolf RR (1997) Hepatic and wholebody fat synthesis in humans during carbohydrate overfeeding. American Journal of Clinical Nutrition 65, 1774-1782.
2. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B & Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary cultures. Molecular Pharmacology 44, 707-715.
3. Acheson KJ, Schutz Y, Bessard T, Ravussin E, Jequier E & Flatt JP (1984) Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal. American Journal of Physiology 246, E62-E70.
4. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, Castaing D & Bismuth H (1991) The outcome of steatotic grafts in liver transplantation. Transplantation Proceedings 23, 1538-1540.
5. Alpers DH, Sabesin SM & White HM (1993) Fatty liver: biochemical and clinical aspects. In Diseases of the Liver, 7th ed., pp. 825-871 [L Schiff and ER Schiff, editors]. Philadelphia, PA: JB Lippincott Company.
6. Barnett CR, Flatt PR & loannides C (1988) Role of ketone bodies in the diabetes-induced changes in hepatic mixed-function oxidase activities. Biochimica et Biophysica Acta 967, 250-254.
7. Black M (1984) Acetaminophen hepatotoxicity. Annual Review of Medicine 35, 577-593.
8. Burt AD, MacSween RNM, Peters TJ & Simpson KJ (1991) Nonalcoholic fatty liver: causes and complications. In Oxford Textbook of Clinical Hepatology, pp. 865-871 [N Mclntyre, JP Benhamou, J Bircher, M Rizetto and J Rodes, editors]. Oxford: Oxford University Press.
9. Cousins MJ, Plummer JL & Hall PM (1989) Risk factors for halothane hepatitis. Australian New Zealand Journal of Surgery 59, 5-14.
10. Day CP & Yeaman SJ (1994) The biochemistry of alcohol-induced fatty liver. Biochimica et Biophysica Acta 1215, 33-48.
11. Eriksson S, Eriksson KF & Bondesson L (1986) Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Medico Scandinavica 220, 83-88.
12. Fiatarone JR, Coverdale SA, Batey RG & Farrell GC (1991) Nonalcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. Journal of Gastroenterology and Hepatology 6, 585-590.
13. Frayn K & Kingman S (1995) Dietary sugars and lipid metabolism in humans. American Journal of Clinical Nutrition 62, Suppl., 250S-263S.
14. Girre C, Lucas D, Hispard E, Menez C, Dally S & Menez JF (1994) Assessment of cytochrome P450 2E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochemical Pharmacology 47, 1503-1508.
15. Horsmans Y, De Konninck X, Geubel A & Pauwels S (1995a) Microsomal function in hepatitis B surface antigen healthy carriers: assessment of cytochrome P-450 1A2 activity by the 14C-caffeine breath test. Pharmacology Toxicology 77, 247249.
16. Horsmans Y, Geubel AP & Pauwels S (19956) Reliability of aminopyrine breath test using a single breath collection. Digestive Diseases and Sciences 40, 1581.
17. Keeffe EB, Adesman PW, Stenzel P & Palmer RM (1987) Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Digestive Diseases and Sciences 32, 441-445.
18. Kharasch E, Hankins D, Mautz D & Thummel KE (1996) Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347, 1367-1371.
19. Krishnaswamy K, Kalamegham R & Naidu NA (1984) Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects. British Journal of Clinical Pharmacology 17, 139-146.
20. Kuwahara M & Hachimura K (1980) Image enhancement and left ventricular contour extraction techniques applied to radioisotope angiocardiograms. Automedica 3, 107-119.
21. Leclercq I, Desager JP & Horsmans Y (1998a) Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single-dose watercress ingestion. Clinical Pharmacology and Therapeutics 64, 144-149.
22. Leclercq I, Horsmans Y & Desager JP (19986) Estimation of chlorzoxazone hydrolase activity in liver microsomes and of the plasma pharmacokinetics of chlorzoxazone by the same highperformance liquid-chromatographic method. Journal of Chromatography 4, 291-296.
23. Lee RG (1989) Nonalcoholic steatohepatitis: a study of 49 patients. Human Pathology 20, 594-598.
24. Mortelmans L, Nuyts Y, Van Pamel G, Van Den Magdenbergh V, De Roo M & Suetens P (1986) A new thresholding method for volume determination by SPECT. European Journal of Nuclear Medicine 12, 284-290.
25. Osawa H & Mon Y (1996) Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. Journal of Clinical Ultrasound 24, 25-29.
26. O'Shea D, Davis SN, Kim RB & Wilkinson GR (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clinical Pharmacology and Therapeutics 56, 359-367.
27. Ploeg RJ, D'Alessandro A, Knechtle S, Stegall MD, Pirsch JD, Hoffmann RM, Sasaki T, Sollinger HW, Beizer FO & Kalayoglu M (1993) Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 55, 807-813.
28. Raucy JL, Lasker JM, Lieber C & Black M (1989) Acetaminophen activation by human cytochromes P450IIE1 and P450IA2. Archives of Biochemistry and Biophysics 271, 270-283.
29. Sheiner LB (1983) ELSFIT (Version 3.0) A program for the extended least squares fit to individual pharmacokinetic data. San Francisco, CA: University of California.
30. Song BJ, Veech RL & Saenger P (1990) Cytochrome P450HE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. Journal of Clinical Endocrinology and Metabolism 71, 1036-1040.
31. Tapner M, Liddle C, Goodwin B, George J & Farrell GC (1996) Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. Hepatology 24, 367-373.
32. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M & Liddle C (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128-133.
33. Yun YP, Casazza JP, Sohn DH, Veech RL & Song BJ (1991) Pretranslational activation of cytochrome P450IIE1 during ketosis induced by a high fat diet. Molecular Pharmacology 41, 474-479.